What is it about?
An important unmet need for new treatment options remains for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) previously treated with both platinum-based chemotherapy and anti-programmed cell death protein 1 (PD-1) antibody. Here, we conducted a phase II trial aimed to evaluate the efficacy and safety of paclitaxel plus biweekly cetuximab for patients in this setting.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
The results of this study showed that combination of paclitaxel plus biweekly cetuximab was highly effective for the treatment of R/M-HNSCC in patients who were previously treated with both platinum-based chemotherapy and PD-1 antibody. Although previous retrospective studies suggested that previous immunotherapy might augment the efficacy of salvage chemotherapy, this is the first prospective study to show promising efficacy for salvage chemotherapy after immunotherapy.
Perspectives
Paclitaxel plus biweekly cetuximab showed highly encouraging efficacy and manageable toxicities in R/M-HNSCC patients previously treated with both platinum-based chemotherapy and PD-1 antibody. This combination therapy warrants further investigation in this setting.
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody, ESMO Open, June 2024, Elsevier,
DOI: 10.1016/j.esmoop.2024.103476.
You can read the full text:
Contributors
The following have contributed to this page
